Microbiology and Immunology

Program Coordinator: Laura Kasman, Ph.D. [email_address]

M&I program currently ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Program Requirements ,[object Object],[object Object],[object Object],[object Object]

Departmental vs. Program Faculty ,[object Object],[object Object],[object Object]

M&I Department Faculty Interests

Bacteriologists ,[object Object]

Immunologists ,[object Object],[object Object],[object Object]

Tumor Immunologists & Gene Therapy ,[object Object],[object Object],[object Object]

Program Faculty ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Program Faculty ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Entrepreneurship by M&I faculty Bacterial electricity generation, Microbial fuel cells Dr. May MFC Tech Therapeutic complement inhibitors Dr. Tomlinson Taligen Ceramide-modifying anti-cancer agents Dr. Norris SphingoGene Adenovirus-based subunit vaccines Dr. Dong GenPhar Technology Faculty Company

MOUNT PLEASANT, SC (AUGUST 30, 2007) - Groundbreaking ceremony for new facility at Innovation Park, in the economic development zone of The Market at Oakland. ,[object Object],[object Object]

James S. Norris, PhD Co-Founder, SphingoGene, Inc. http://www.sphingogene.com Professor and Chairman, MUSC [email_address] SphingoGene, Inc. SphingoGene, Inc. is focused on commercialization of small molecule therapeutics that modify ceramide metabolism to overcome resistance to chemo and radiation therapy and promote apoptosis in cancer cells. Ceramide is a “tumor suppressor sphingolipid” involved in regulation of cell death. SphingoGene, Inc.’s molecules are rationally designed and proven to inhibit enzymes that create resistance to conventional cancer therapies. Our goal is to utilize these small molecules in combination with “standard of care” radiation or chemotherapy to enhance cancer cell death. ,[object Object],[object Object],[object Object],[object Object],[object Object],Products and Services N H C O O H 1 2 O H (2S, 3R, 4E) D- erythro -Ceramide 3 4 5 n

Controlling Inflammation to Treat Human Disease Applying novel technologies to create better treatments Contact: Woodruff Emlen MD [email_address] Taligen Therapeutics, Inc. is a development stage biotechnology company with novel technology to modulate and regulate activation of the complement system. Inappropriate complement activation leading to inflammation is a major contributor to a large number of human diseases. Taligen has proof of concept data in animal models of diseases as diverse as asthma, macular degeneration, immune renal disease, inflammatory arthritis, ischemia-reperfusion injury, stroke and traumatic brain injury. Product Development Currently focused on the areas of asthma and age related macular degeneration. Stephen Tomlinson, PhD Professor [email_address]

Dr. Hal May, Ph.D. VP, MFC Technologies LLC http://www. mfctech .net hmay @ mfctech .net Assoc. Prof. MUSC mayh @ musc . edu Microbially Generated Electricity Increase Biofuel Production 24/7 Remote Power, Sensor Control Control Waste, Odor and Algae

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Microbiology and Immunology

Recommended

Recommended

More Related Content

Similar to Microbiology and Immunology

Similar to Microbiology and Immunology (20)

More from MedicineAndHealth14

More from MedicineAndHealth14 (20)

Recently uploaded

Recently uploaded (20)

Microbiology and Immunology